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ABSTRACT
Introduction: Women diagnosed with cancer and
facing potentially sterilising cancer treatment have to
make time-pressured decisions regarding fertility
preservation with specialist fertility services while
undergoing treatment of their cancer with oncology
services. Oncologists identify a need for resources
enabling them to support women’s fertility preservation
decisions more effectively; women report wanting more
specialist information to make these decisions. The overall
aim of the ‘Cancer, Fertility and Me’ study is to develop
and evaluate a new evidence-based patient decision aid
(PtDA) for women with any cancer considering fertility
preservation to address this unmet need.
Methods and analysis: This is a prospective mixed-
method observational study including women of
reproductive age (16 years +) with a new diagnosis of
any cancer across two regional cancer and fertility
centres in Yorkshire, UK. The research involves three
stages. In stage 1, the aim is to develop the PtDA
using a systematic method of evidence synthesis and
multidisciplinary expert review of current clinical
practice and patient information. In stage 2, the aim is
to assess the face validity of the PtDA. Feedback on its
content and format will be ascertained using
questionnaires and interviews with patients, user
groups and key stakeholders. Finally, in stage 3 the
acceptability of using this resource when integrated
into usual cancer care pathways at the point of cancer
diagnosis and treatment planning will be evaluated.
This will involve a quantitative and qualitative
evaluation of the PtDA in clinical practice. Measures
chosen include using count data of the PtDAs
administered in clinics and accessed online, decisional
and patient-reported outcome measures and qualitative
feedback. Quantitative data will be analysed using
descriptive statistics, paired sample t-tests and
CIs; interviews will be analysed using thematic
analysis.
Ethics and dissemination: Research Ethics
Committee approval (Ref: 16/EM/0122) and Health
Research Authority approval (Ref: 194751) has been
granted. Findings will be published in open access
peer-reviewed journals, presented at conferences for
academic and health professional audiences, with
feedback to health professionals and program
managers. The Cancer, Fertility and Me patient decision
aid (PtDA) will be disseminated via a diverse range of
open-access media, study and charity websites,
professional organisations and academic sources. External
endorsement will be sought from the International Patient
Decision Aid Standards (IPDAS) Collaboration inventory
of PtDAs and other relevant professional organisations,
for example, the British Fertility Society.
Trial registration number: NCT02753296; pre-results.
Strengths and limitations of this study
▪ To the best of our knowledge, this research will
develop the first, open access, evidence-based
fertility preservation decision aid that is suitable
for women of reproductive age (16 years+) and
diagnosed with any cancer.
▪ The research will provide evidence of its accept-
ability and utility to women and healthcare pro-
fessionals in usual practice across cancer and
fertility care pathways.
▪ The research will provide evidence for the causal
assumptions of its effectiveness and issues for
implementation in usual care practice.
▪ This research will not provide evidence of its
effectiveness on healthcare outcomes. However,
our findings will provide the evidence to inform
the study design for evaluating the effectiveness
of this complex intervention on health outcomes
in the future.
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INTRODUCTION
The impact of cancer treatment on female fertility
Approximately 50% of people in the UK will be diag-
nosed with cancer at some point in their lifetime.1
Owing to rising survival rates, the importance of addres-
sing the late effects of cancer treatment, such as the risk
of infertility, has increased.2 Chemotherapy, radiother-
apy, hormonal, medical and surgical interventions may
all affect female fertility. Although, the degree to which
chemotherapy and radiotherapy impacts on gonadal
function depends on the treatment agent administered,
the dose, as well as the woman’s age and levels of
ovarian reserve at the time,3–5 loss of fertility is consid-
ered one of the most signiﬁcant late effects of cancer
treatment3 and cancer survivors often report it as one of
the most distressing outcomes of their cancer
treatment.6
The rationale for the study
Women diagnosed with cancer have to make time-
pressured decisions about fertility preservation while
simultaneously planning their cancer treatment. These
decisions are stressful as women are having to trade-off
the immediate consequences of starting cancer treat-
ment with the long-term chances of having a biological
child in the future, post cancer treatment. For those
contemplating fertility preservation, women are required
to move between two medical services (oncology and fer-
tility services) to make care planning decisions collabora-
tively with fertility preservation and cancer teams.
In the initial stages of treatment for cancer, the
American Society of Clinical Oncology and the
American Society for Reproductive Medicine recom-
mend options to preserve fertility which are discussed
with each patient of reproductive age about to undergo
cancer treatment which may affect their fertility.7 8 The
current National Institute for Clinical Excellence
(NICE) pathway for preserving fertility in people diag-
nosed with cancer presents similar guidelines for the
UK.9 However, the evidence suggests that many women
do not feel well supported in their choices, with many
missing out on having fertility preservation at this crucial
time. A recent UK survey by Breast Cancer Care found
that as little as 12% of 170 women were referred to a fer-
tility consultant, with many being unaware that infertility
was a consequence following chemotherapy.10
Evidence from the medical and psychological litera-
ture examining aspects of fertility, pregnancy and
decision-making following a cancer diagnosis have iden-
tiﬁed a range of factors which may hinder decision-
making for this patient population.11–25 The barriers
identiﬁed are diverse including ﬁnancial concerns (espe-
cially in those countries where fertility preservation is
not covered by insurance), fear associated with aggravat-
ing a hormone-sensitive cancer or a future pregnancy
(in terms of a cancer recurrence and/or implications
for the health of a future child) and lack of referral to
fertility services (eg, due to reasons such as the oncolo-
gist prioritising cancer survival).
However, lack of fertility preservation information is
also a key reason cited. The need for more evidence-
based information that is integrated into the cancer care
pathway early, and prior to transition to fertility services,
has been identiﬁed as an important factor to facilitate
women’s decision-making at this time.26 27 It has been
found that oncologists lack speciﬁc fertility preservation
information for patients, and have only moderate conﬁ-
dence in their knowledge about fertility and the preser-
vation options available.28 Therefore, they have also
expressed the need for more evidence-based fertility
preservation information to enable them to support
women’s decision-making more effectively.29
Patient decision aids
Patient decision aids (PtDAs) are information resources
supporting people to make decisions between health-
care options.30 They are evidence-based resources,
drawing on clinical effectiveness of healthcare options
data, studies of patients’ decision-making and illness
experiences and evidence from the decision sciences on
how people make healthcare choices.31 PtDAs support
people to make reasoned decisions, that is, ones based
on accurate information about the consequences of all
options, in accordance with their beliefs, and trade-offs
between their treatment preferences.32–34 Compared
with usual care, receiving a PtDA helps people partici-
pate with their health professionals in making persona-
lised choices between healthcare options.32 33 They have
been shown to improve patients’ knowledge of the risks
and beneﬁts of options, value of consequences to their
lives and efﬁcacy in making informed decisions.30
While there are many fertility preservation resources
publically available for women with cancer,35 few exist to
support the fertility preservation decision process in
women of reproductive age.35 Of those publishing their
development studies, two PtDAs were designed for
women with breast cancer speciﬁcally, and none for
women in the UK,36 37 despite women with a range of
different cancers facing fertility preservation treatment
decisions. It is therefore likely a new PtDA supporting
women diagnosed with any cancer to make fertility pre-
servations decisions will meet patient, service and prac-
tice needs.25 26 35
AIMS AND OBJECTIVES
The aim of this research is to develop a fertility preserva-
tion PtDA enabling cancer and fertility services to
support effectively women’s fertility preservation deci-
sions following a diagnosis of any cancer type.
Our objectives are to:
1. develop a PtDA for use by oncology and haematology
teams to support women making fertility preservation
choices, while having a recent cancer diagnosis;
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2. assess the face validity of the PtDA to support women
making informed decisions about fertility preserva-
tion before starting their cancer treatment and
3. evaluate the acceptability of the PtDA using qualita-
tive and quantitative methods to 1) women making
fertility preservation decisions while planning their
cancer treatment and 2) oncology, haematology and
fertility health professionals supporting women’s
cancer and fertility treatment choices.
Evaluation of the PtDA should enable us to determine
whether the provision of a PtDA early in the cancer care
pathway better supports women, especially in the stress-
ful intervening period between planning their cancer
treatment and referral to the fertility expert. We also
anticipate that the provision of this PtDA will enable
women to make more informed fertility preservation
treatment decisions, have more focused consultations
with the fertility experts and a better opportunity to ask
the right questions for them at the right time.
METHODS AND ANALYSIS
All aspects of the research are discussed with the steer-
ing group, and all stakeholders comment on all the
materials. There has been patient and public
involvement in the development of the research proto-
col and initial needs assessment. The PtDA is being
developed across two regional cancer (adult, and
teenage and young adult services) and fertility centres
in Yorkshire. Ethics approval was granted on 5 April
2016.
Design
The Cancer, Fertility and Me PtDA was developed over
a year using systematic and evidence-based methods
(table 1—stages 1 and 2).33 38 39 A prospective, observa-
tional study using interview and questionnaire methods
to evaluate the PtDA will be conducted (table 1—stage
3) informed by Medical Research Council Guidance for
Developing Complex Interventions.40
Stage 1: Development of the PtDA (November 2015—July
2016)
Stage 1 has used evidence to develop a PtDA supporting
women to make informed decisions about fertility pres-
ervation options before starting cancer treatment. This
will be for use alongside usual cancer and fertility care
pathways.
Table 1 The three stages of the Cancer, Fertility and Me study
Stages Methods Data collection Sample
Stage 1:
development of
the PtDA
Identifying the
active ingredients
of the PtDA
IPDAS checklist and evidence articles
used as a framework for development.
Evidence synthesis of women with
cancer’s experience of making FP
decisions. Evidence from clinical
guidelines and best practice.
Review of current practice—service
delivery and patient resources.
Iterative development process.
Study team, steering group with
cross-sector expertise, oncologists,
haematologists, fertility experts, decision
scientist, relevant charity organisations,
stakeholders and service users/PPI
panel supporting the study.
Stage 2: face
validity
Quantitative LV questionnaire (comprising of 4 items
taken from the QQ-10 and some open
questions), and the Preparation for
Decision-making questionnaire.
10 women (5 from each site).
10 health professionals (5 from each
site).
+
Women and key health professionals
from the relevant user groups and
organisations identified by The Cancer,
Fertility and Me steering group and
systematic reviews.
Qualitative Semi-structured telephone interviews. The same 10 women and health
professionals.
+
Additional women and key health
professionals described above.
Stage 3:
evaluation
Quantitative EQ-5D, State Trait Anxiety. 78 women (in total from both sites).
(baseline, time 1,
time 2a)
Inventory, Stage Of Decision-Making,
Decisional Conflict Scale, preparation for
decision-making, count data.
3a
3b Qualitative (time
2b)
Semi-structured interviews, EQ-5D,
Decisional Regret Scale.
30 women and health professionals (in
total from both sites).
EQ-5D, EuroQol five dimensions questionnaire; FP, fertility preservation; IPDAS, International Patient Decision Aid Standards; PPI, Patient
and Public Involvement; PtDA, patient decision aid.
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The PtDA has used guidance from the International
Patient Decision Aid Standards (IPDAS) collaboration34
on balance of options,41 42 risk presentation,43–45 elicit-
ing values,46 47 use of patient stories,30 enabling readabil-
ity48 and understanding illness.49 50 The guidance helps
information to be structured so that it encourages
people to evaluate all decision options, and their conse-
quences, in accordance with their values and without
bias, thus, enabling decision-making to be based on
their trade-offs between these evaluations, that is, to
make a reasoned decision.34
The aim is for women to receive the PtDA from their
cancer health care professionals as part of usual care
during the patient’s ﬁrst consultation to discuss cancer
and/or fertility treatment options (this could be at
cancer diagnosis), before referral to fertility services.
The PtDA is being disseminated as a leaﬂet and PDF on
a website, and evaluated accordingly. The content of the
PtDA will be informed by evidence from the following:
▸ Clinical guidelines on infertility and cancer progno-
sis, risks and beneﬁts of cancer and fertility preserva-
tion treatment.8–9 35
▸ Systematic narrative review of women’s values, treat-
ment preferences and decision-making experiences
about fertility preservation when diagnosed with
cancer, completed in June 2016. This was carried out
as part of the previous PreFer study which was a
3-year mixed-methods prospective study exploring fer-
tility preservation decision-making and quality of life
in women with cancer.25
▸ Environmental scan using systematic methods to syn-
thesise evidence about open access resources for
women with cancer about fertility preservation
(patient information and clinical guidelines) and crit-
ically evaluate their ability to support informed
decision-making, completed in May 2016.35
▸ Observations of local service delivery, referral path-
ways within and across services and integration of
research practices across regional National Health
Service (NHS) centres for cancer and infertility ser-
vices, completed by June 2016.
Regular meetings with the study steering group to
decide the content and design of the PtDA. During this
time web and graphic designers were involved in devel-
oping the PtDA’s identity for use in health and patient
forums, completed by July 2016.
Stage 2: Face validity study ( July 2016–December 2016)
Stage 2 assesses the face validity of the PtDA for stake-
holders. During the development of decision aids, this
process is sometimes referred to as Learner Veriﬁcation
(LV).51 The aim is to assess the PtDA across stakeholders
for attractiveness, comprehension, cultural acceptability,
self-efﬁcacy and persuasion.52 53
Sample
A purposive sample of eligible women and health profes-
sionals will be invited to participate from the study sites.
All women of reproductive age (16 years +), diagnosed
with any cancer and undergoing or has undergone
cancer treatment(s) which may impact fertility will be
eligible. The sample of health professionals will consist
of adult and paediatric oncologists and haematologists,
cancer surgeons, cancer nurse specialists and fertility
specialists (clinicians, nurses and counsellors).
There is no statistical guidance for undertaking LV
methods using qualitative methods. Prior literature and
our research experience suggest a sample size of 20 par-
ticipants in total across both sites to be appropriate.54
Therefore, 10 women and 10 health professionals from
the two clinical centres will be invited to participate. In
addition to the 20 participants, women and key health
professionals will be invited to participate from relevant
user groups/forums and professional organisations iden-
tiﬁed by the Cancer, Fertility and Me steering group and
our systematic reviews (eg, National Cancer Research
Initiative, Breast Cancer Care and British Fertility Society
among others).
Recruitment
To recruit the women to stage 2, the nurses/clinicians
will make the initial approach (for those women
recruited from the two clinical centres). For the women
recruited through the service user groups/forums, the
lead contacts for the service user groups will make the
initial approach. Following this, the contact details of the
interested women will be passed to a trained researcher
and those willing to participate will be sent the PtDA and
associated documents to review by post. Recruitment of
health professionals will be obtained from the study sites
and through purposive and snowball sampling for the
key stakeholders. The PtDA will be sent by post or via a
PDF online depending on the request of the health pro-
fessional. Appropriate consenting procedures and guide-
lines prescribed by the British Psychological Society55
and NHS research protocols will be followed.
Data collection
All the women and health professionals will be asked to
complete a study questionnaire which includes the LV
questionnaire, and the Preparation for Decision-making
questionnaire.56 The LV questionnaire will consist of
four items taken from the QQ-10,57 but will also com-
prise of three open-ended questions relating to the
acceptability and utility of the PtDA from women’s and
health professional’s perspective. The Preparation for
Decision-making scale56 is a 10-item measure which
assesses an individual’s perception of how useful a PtDA
is in preparing the respondent to communicate with
their practitioner at a consultation focused on making a
health decision. High scores on the overall scale (range
0–100) indicate higher perceived levels of preparation
for decision-making.
Second, all the health professionals and women who
completed the questionnaire and consent form, will be
asked to take part in a follow-up telephone interview. An
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interview schedule will be used to seek their feedback
and understanding of the purpose of the PtDA and
study measures.51 53 Interviews will be audio recorded,
digitalised and transcribed for analysis.
Data analysis
Telephone interviews will be coded and managed using
NVivo 10 qualitative data analysis software. Analysis will
use a practical, thematic approach outlined by Braun
and Clarke58 using a systematic ﬁve-step approach: famil-
iarisation, generating initial codes, searching for themes,
reviewing themes and deﬁning and naming themes.
Stage 3: Evaluation study ( January 2017–May 2018)
Stage 3 evaluates the acceptability, feasibility and useful-
ness of the PtDA in clinical practice with women and
health professionals. The study design employs mixed
methods, using quantitative (stage 3a) and qualitative
methods (stage 3 b).
Stage 3a Quantitative sample
All women receiving a new diagnosis of cancer from two
regional centres will be eligible for participation.
Inclusion criteria are women of a reproductive age
(16 years +) with a new diagnosis of any cancer, and
facing cancer treatment(s) with curative intent, which
may impact fertility. We anticipate that the majority will
be women with breast cancer, although women with
lymphoma and leukaemia, head and neck cancers and
cervical cancers are also likely to be represented in this
research. From the results of our previous PreFer
study,13 we have found that ∼90 women, across both hos-
pital sites, aged between 16 and 40 years are diagnosed
with cancer and face chemotherapy treatment annually
and are eligible to receive the new PtDA. We identiﬁed
around 17% of women from this group do not wish to
consider fertility preservation as they already have chil-
dren or never wanted children. During the 12-month
period we hope to recruit ∼78 women in total, taking
into account a 20% non-response rate from our previous
data. Using a paired t-test to compare the outcome mea-
sures before and after the implementation of the PtDA,
with 78 participants, we have 80% power at 5% two-sided
signiﬁcance to detect a minimum standardised effect
size of 0.32.
Stage 3a Quantitative recruitment
We will adopt the ‘referral model’ for implementing the
PtDA59 that is, the PtDA will be mentioned and dis-
cussed by their healthcare professional with any woman
ﬁtting the eligibility criteria during the patient’s ﬁrst
consultation to discuss treatment options. The referral
model proposes that these tools are ‘adjuncts’ that
support decision-making, when used ahead of visits, or
shortly afterwards.59 Eligible women will be invited to
participate by the researchers working with the clinical
care team, immediately following this consultation.
Stage 3a Quantitative data collection
Quantitative data will be collected at three time-points
(ﬁgure 1). Questionnaire packs will be given to women
at the same time as the PtDA (baseline); the timing of
their attendance at the fertility clinic or cancer treat-
ment starting point if not going to fertility services (time
1) and after their ﬁrst session of chemotherapy (time
2a). The measures chosen for this study have been
decided on following recommended guidance from the
Patient Decision Aid International Research Group,60
and will assess the use of the PtDA and decisional
preparedness.
Baseline: questionnaire pack includes: The State Trait
Anxiety Inventory—STAI-6,61 the EuroQol ﬁve dimen-
sions questionnaire (EQ-5D),62 the Stage of
Decision-making63 and the Decisional Conﬂict Scale.64
Women are instructed not to open and read the PtDA
(or access it online) until they have completed the
questionnaires.
The State Trait Anxiety Inventory—6 item45 is a brief
6-item version used to measure of state anxiety. All items
are rated on a 4-point scale (1-Almost never, 4-Almost
always). Higher scores indicate greater anxiety. The
EQ-5D62 is a standardised instrument for use as a
measure of health outcome. It consists of ﬁve dimen-
sions: mobility, self-care, usual activities, pain/discomfort
and anxiety/depression. Each dimension has three
levels: no problems, some problems and extreme pro-
blems. The Stage of Decision-making63 is a 6-category
tool to assess the individual’s readiness to engage in
decision-making, progress in making a choice and recep-
tivity to considering or reconsidering options. The tool
is rated on a 6-point scale (1-not thinking about it at all;
6-considered the options). The Decisional Conﬂict
Scale64 is a 16-item scale which measures the patient’s
reported experience of making a reasoned and/or con-
ﬂicted decision.
Scores >37.5 on the overall scale (range 0–100) indi-
cate high decisional conﬂict, which is characterised by
decision delay and/or uncertainty about decision.
Time 1: Questionnaire pack includes: the STAI-6,45
the Stage of Decision-making63 and the Preparation for
Decision-making.56
Time 2a: Questionnaire pack includes: the STAI-6,45
the Stage of Decision-making63 and the Decisional
Conﬂict Scale.64
Stage 3a Quantitative data analysis
We will report summary statistics for the count data and
other service indicators. For the decisional outcome
measures and other patient-reported outcomes we will
use paired sample t-tests to calculate mean change in
scores from baseline to time 1 and from baseline to time
2. 95% CIs for the mean changes will also be calculated.
All statistical tests will be two-tailed with signiﬁcance
determined at p≤0.05.
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Stage 3b Qualitative sample
Qualitative, semistructured interviews with a purposive
sample of ∼30 women from the stage 3a evaluation (15
women from each site) and 30 health professionals
including cancer surgeons, adult and paediatric oncolo-
gists and haematologists, nurse specialists and fertility
experts (15 from each site) will be carried out. The
purpose of the interviews are to gain a deeper sight into
service user and healthcare professionals experiences of
using the PtDA and its impact on the decision- making
process and clinical care, within the context of this
complex intervention.40 Although a total of ∼30 inter-
views are estimated, this will be guided by data satur-
ation, following established protocols in qualitative
research.58 65 66
Stage 3b Qualitative recruitment
The sample will consist of the women recruited into the
stage 3 quantitative study, and the clinical sample will be
obtained through snowball sampling methods. Women
and health professionals will be issued with a study pack,
including a study information sheet and the PtDA. On
the day of the interview, an interview consent form will
be completed. As shown in
Figure 1, the interview with women and the health
professionals will be carried out after the ﬁrst round of
chemotherapy has been completed (time 2b) at a place
that is most preferred.
Stage 3b Qualitative data collection
The interview schedule will comprise of the telephone
interview LV schedule used in stage 2, with additional
open-ended questions to add depth and breadth to the
interpretation of the quantitative results enabling
further insight into their experiences. It will also focus
on LV and the PtDAs clarity and usefulness in planning
care and making decisions between treatment options.
However, additional areas we will explore include the
PtDAs likelihood of use, barriers to use in practice,
whether or not the women and health professionals
beneﬁt from their delivery, usefulness of the PtDA in
aiding service transition and how the women used the
PtDA.
Figure 1 Process flow chart for stage 3 evaluation study.
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All interviews will be audio-recorded and transcribed
verbatim for analysis. Following the interview, the
women will be given a ﬁnal study pack questionnaire to
complete, which comprises of the EQ-5D62 and the
Decisional Regret Scale.67 The Decisional Regret Scale is
a brief ﬁve-item scale which measures ‘distress or
remorse after a health care decision’ using a 5-point
Likert scale (1- strongly agree; 5- strongly disagree). A
score of 0 on the overall scale (range 0–100) indicates
no regret; scores of 100 mean high regret.
Stage 3b Qualitative data analysis
Interviews will be coded and managed using NVivo 10.
Framework analysis will be carried out to identify re-
current themes which have been speciﬁcally developed
for applied health and policy research.68 Independent
analysis of the transcribed data by members of the
study team and steering group will take place.
Interdisciplinary analysis meetings will include critical
appraisal of the literature, systematic data and coding
framework veriﬁcation and challenging of interpretive
analysis. We will map the data against the themes identi-
ﬁed from the existing literature as well as allow new
themes to emerge. We will adhere to established quality
criteria for qualitative research.58 65 66
Other questionnaires and outcome measures
Demographic information about women’s age, ethnicity,
employment and treatment status will be collected
through a questionnaire during stage 2 (face validity)
and at stage 3 baseline. Demographic information about
health professionals will also be collected through a
questionnaire, during stage 2 and at stage 3 (time 2b).
Details of patients’ cancer treatment(s) will be recorded
at the end of the study using a study ‘cancer treatment
proforma’. This proforma has been ethically approved
and used to record the cancer treatment details in the
previously mentioned PreFer Study.26
Count data will be collected of the number of PtDAs
given to women and health professionals, counts of use
and number of clicks on the ‘Cancer, Fertility and Me’
website and downloads of the online PDF version will be
recorded. In addition, we will record length of oncology,
haematology and fertility consultations and length of
time to fertility and cancer treatment. Using count data
is a common method for evaluating a decision aid.69
ETHICS AND DISSEMINATION
Ethical considerations
Written, signed consent will be obtained from all partici-
pants. Issues particularly pertinent to this study will
include participants’ right to withdraw from the research
process, informed consent and their right to conﬁdenti-
ality and anonymity. Usual NHS care will be provided by
the health professionals involved, which includes referral
to support and counselling services available within the
oncology, haematology and fertility services at the NHS
study sites, if any of the women wish. In line with good
practice, across both sites, the young women aged 16–
17 years and their parents/guardians will be asked to
sign for consent.
Dissemination
This research will involve rigorous methods and evalu-
ation in a clinical context.40 The multidisciplinary and
collaborative nature of this proposal will enable us to dis-
seminate the research and its milestones to the study
participants and into the NHS and wider healthcare
community through a variety of local, national and inter-
national channels regularly throughout the duration of
this research.
During the development and evaluation phases of the
research, we are engaging with patients and the public
through the North Trent Consumer Research Panel
group, NHS England’s Patient Involvement Team,
International Cancer Patient Voices, the service user
research partnership of Breast Cancer Care as well as
presenting our ﬁndings at INVOLVE national confer-
ences. A study website is currently under development
(http://www.leedsbeckett.ac.uk/cancerfertilityandme.ac.
uk).
It will be used to provide an evidence-based portal on
the study, team and links with our international part-
ners. It will enable access to the web-based version of the
instrument and provide two-way links into other relevant
organisations, charities signposted on our webpage and
the other social media planned to be used in the study,
for example, twitter/blogs. We plan to impact the aca-
demic and clinical community more widely through con-
ference presentations and publications in peer-reviewed
journals that are open access.
Findings on the quality of the PtDA and study out-
comes will be used to provide feedback to health profes-
sionals and programme managers. Audit and feedback is
an effective intervention for changing the behaviour of
health professionals (Cochrane Effective Practice and
Organisation of Care Group). The study will be widely
and regularly disseminated throughout its duration.
We will develop links with NHS England patient infor-
mation teams and other UK and international bodies
who endorse patient education materials for use/dissem-
ination by service teams. We will also seek assessment by
the international criteria of PtDAs to be included in
their A to Z inventory.60
The primary output of this study will be the ﬁnal
version of the PtDA. Once evaluated, it will be promoted
widely and made available free through a diverse range
of media (ie, social and print), charity websites, profes-
sional organisations, academic sources and posted to all
key stakeholders and participants.
DISCUSSION
It is anticipated that this research will provide evidence
about the effectiveness of a PtDA to support cancer
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patients’ decision-making in relation to fertility preserva-
tion. Currently, fertility preservation PtDAs for women
of reproductive age only exist to support women with
breast cancer. A unique feature of this research is that
we hope to provide evidence that one open-access PtDA
can be used effectively across a range of women’s cancer
types. Another strength of this research is that it will be
administered early into the cancer care pathway, thus
providing clinical cancer care teams with an evidence-
based resource to provide to all women diagnosed with
cancer, therefore meeting a current unmet need. It is
anticipated that this will encourage more cancer specia-
lists to have fertility related discussions with women, help
raise fertility awareness and provide a resource that will
improve the care, support and management of the
women.
While this might result in more women choosing to
see the fertility expert (Breast Cancer Care alone esti-
mated that around 5000 women per year who should be
having this consultation are missing out), it should also
reduce the number of women with cancer who are
inappropriately referred for fertility preservation and
unsuitable for this treatment.
In trying to create a resource that is suitable for
women with any cancer, this undoubtedly creates a
number of challenges (in terms of synthesising the evi-
dence on cancer treatment on female reproduction and
the fertility preservation choices available). We have
tried to prepare for this and included an extensive face
validity stage during which the PtDA will undergo review
from a large number of patients, service users and key
stakeholders from a variety of oncology and fertility
specialities.
The overall aim of the ‘Cancer, Fertility and Me’ study
is to develop and evaluate a new evidence-based PtDA
for women with any cancer considering fertility preserva-
tion. The data generated as part of this study should
help us identify factors associated with its implementa-
tion in practice, and/or integration in care. During its
evaluation, the cancer care clinical teams will hand out
information about the study and the PtDA. We will
capture data on the acceptability of this method of inte-
gration within care from the clinical teams. It may be
our clinical teams think a short skills training session on
using our PtDA within cancer and fertility services will
support its implementation in usual practice. It is likely
future research evaluating our PtDA’s impact on health
outcomes may therefore also need to include an assess-
ment of shared decision-making training within an
implementation study’s process evaluation.
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